ArticleJournal of virology2002
Parameters of human hepatitis delta virus genome replication: the quantity, quality, and intracellular distribution of viral proteins and RNA.
Article in Journal of virology, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 94 citations in OpenAlex.
- Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial.The Lancet. Infectious diseases · 2015Trial
- Long-term therapy of chronic delta hepatitis with peginterferon alfa.Alimentary pharmacology & therapeutics · 2014Trial
- Sensitive reverse transcription-digital droplet PCR-based discrimination of hepatitis delta virus RNAs reveals differential effects of interferon-α on viral RNA species.The Journal of general virology · 2026Article
- Natural immune escape mutations in the envelope proteins of hepatitis B virus (HBV) regulate the assembly and infectivity of human hepatitis delta virus (HDV).Journal of virology · 2026Article
- Structural characterization of the HDV virion and its ribonucleoprotein.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- An hepatitis B and D virus infection model using human pluripotent stem cell-derived hepatocytes.EMBO reports · 2024Article
- Prevalence and clinical characterization of hepatitis D virus (HDV) infection among Sudanese patients with hepatitis B virus (HBV): a cross-sectional study.Annals of medicine and surgery (2012) · 2024Article
- Article
- Advances and Challenges in Managing Hepatitis D Virus: Evolving Strategies.Current hepatology reports · 2024Article
- Diagnosis of HDV: From virology to non-invasive markers of fibrosis.Liver international : official journal of the International Association for the Study of the Liver · 2023Review
- Epidemiology and Risk Factors for Acute Viral Hepatitis in Bangladesh: An Overview.Microorganisms · 2022Review
- Hepatitis D virus (HDV): investigational therapeutic agents in clinical trials.Expert opinion on investigational drugs · 2022Review
- Adaptive Immune Responses, Immune Escape and Immune-Mediated Pathogenesis during HDV Infection.Viruses · 2022Review
- Multiple Regions Drive Hepatitis Delta Virus Proliferation and Are Therapeutic Targets.Frontiers in microbiology · 2022Review
- HDV-Like Viruses.Viruses · 2021Review
- Review
- Review
- Innate immune recognition and modulation in hepatitis D virus infection.World journal of gastroenterology · 2020Review
- Hepatitis D infection: from initial discovery to current investigational therapies.Gastroenterology report · 2019Article
- Generation and characterization of a stable cell line persistently replicating and secreting the human hepatitis delta virus.Scientific reports · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Assembly of hepatitis delta virus (HDV) in infected human hepatocytes involves association of the 1,679- nucleotide single-stranded genomic RNA (deltaRNA) with multiple copies of both small and large forms of the delta protein (deltaAg) to form a ribonucleoprotein particle which in turn interacts with envelope proteins of the natural helper virus, hepatitis B virus. Subsequently, for initiation of a new round of replication, the amount of small deltaAg within the assembled HDV particle is both necessary and sufficient. Quantitative assays were used in order to better understand just how much deltaAg is needed. The molar ratio of deltaAg species to genomic deltaRNA in assembled HDV particles was approximately 200. Next, this ratio was determined for cells under several different experimental situations in which HDV genome replication was occurring. These included replication in woodchuck liver and also in mouse liver and skeletal muscle, as well as replication in stably and transiently transfected cultured human hepatoblastoma cells. Surprisingly, in almost all these situations the molar ratios were comparable to that observed for HDV particles. This was true for different times after the initiation of replication and was independent of whether or not virus assembly was occurring. Cell fractionation combined with quantitative assays was used to test whether the majority of deltaAg and deltaRNA were colocalized during HDV replication in transfected cells. The cytoplasmic fraction contained the majority of deltaAg and genomic deltaRNA. Finally, the quality of deltaAg and deltaRNA, especially at relatively late times after the initiation of replication, was examined by using reverse transcription-PCR, cloning, and sequencing through the entire deltaAg open reading frame. When virus assembly and spread were not possible, 20% or less of the predicted deltaAg would have been able to support HDV replication. In summary, an examination of the quantity, quality and intracellular distribution of deltaAg and deltaRNA in several different experimental systems has provided a better understanding of the parameters associated with the initiation, maintenance, and ultimate decline of HDV genome replication.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.